Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2014

View Archived Issues

Merz signs agreement with Brickell Biotech for novel retinoid therapy

China's regulatory authority approves phase II trials of F-351

Transcept Pharmaceuticals and Paratek Pharmaceuticals to merge

Pharmacodynamic effects of AZD-3241 revealed in PD patients

Osteogenesis improved in patients with hypophosphatasia

Johnson & Johnson completes divestiture of Ortho-Clinical Diagnostics

FOXO1 as a potential therapeutic target for diabetes demonstrated with AS-1842856

Vertex Pharmaceuticals discloses new ATR inhibitors for cancer

New CB2 receptor agonists patented by Roche

Allergan obtains FDA approval for Ozurdex and updates progress of key programs

Roche designs new SCD inhibitors for cancer

Agenus reports final results from phase II study of Prophage in newly diagnosed GBM

Rigel Pharmaceuticals divulges novel PKC inhibitors for ocular disorders

Researchers in the U.S. and China disclose new agents for cancer and other disorders

Genocea discloses 12-month follow-up data from phase I/IIa trial of HSV vaccine

Boston Strategics forms licensing deal with Eisai for E-6201

Scientists at Pierre Fabre design novel NMDA receptor antagonists

Synageva BioPharma reports topline data from phase III study of sebelipase alfa

Phase I first-in-human study begins for GLPG-1690

Insys Therapeutics receives FDA orphan drug designation for CBD

Genentech to acquire Seragon Pharmaceuticals

Oncoceutics presents preclinical data on lead compound

FDA grants priority review to nintedanib NDA for IPF

Taiho Pharmaceutical seeks additional indication approval in Japan for Zosyn

Rifaximin achieves endpoint in phase III trial in IBS with diarrhea

Boehringer Ingelheim files MAAs for tiotropium/olodaterol combination in Europe

Actavis completes Furiex acquisition

Pozen resubmits aspirin/omeprazole NDAs to the FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...